泰迪实验室（冠和制药）与LabConnect签署战略合作协议，共同开创实验室服务合作新天地-动脉网

Teddy Laboratory (GuanHe Pharmaceuticals) Signs Strategic Cooperation Agreement with LabConnect to Forge a New Landscape in Laboratory Services Collaboration

CISION 等信源发布 2025-05-30 04:30



可切换为仅中文







JOHNSON CITY, Tenn.

田纳西州约翰逊城

，

May 29, 2025

2025年5月29日

/PRNewswire/ --

Teddy Laboratory

泰迪实验室

, a subsidiary of Tigermed, officially signed a strategic cooperation agreement with

，泰格医药的子公司，与正式签署战略合作协议

LabConnect

实验室连接

, LLC, a global leader in central laboratory services. The two parties will jointly build a full-chain laboratory service system covering both

，LLC，全球中心实验室服务的领导者。双方将共同打造覆盖全产业链的实验室服务体系

China

中国

and international markets to accelerate the development and commercialization of innovative drugs worldwide.

加速创新药物在全球的研发和商业化进程。

With this agreement, Teddy Laboratory will become LabConnect's preferred laboratory partner in

通过该协议，泰迪实验室将成为LabConnect的首选实验室合作伙伴。

China

中国

, providing lab services that meet international regulatory standards and supporting multinational pharmaceutical companies conducting clinical trials in

，提供符合国际监管标准的实验室服务，并支持跨国制药公司在以下地区进行临床试验：

China

中国

. Meanwhile, LabConnect will become

同时，LabConnect将变为

Teddy Lab's

泰迪实验室

preferred central lab partner for overseas operations, leveraging its extensive presence in key markets such as

首选的海外运营中心实验室合作伙伴，利用其在关键市场（如

North America

北美

and

和

Europe

欧洲

to help Chinese pharmaceutical companies expand globally.

帮助中国制药企业走向全球。

Teddy Laboratory and LabConnect will establish a long-term preferred partnership, forming a complementary model of '

泰迪实验室与LabConnect将建立长期优先合作伙伴关系，形成互补模式

China

中国

-based capabilities + global service network.' 'By fully leveraging our respective resources and technological strengths, we aim to further enhance global clinical trial service standards,' said

“通过充分利用我们各自的资源和技术优势，我们旨在进一步提升全球临床试验服务标准，”他表示。

Jeff Mayhew

杰夫·梅休

Chief Development Officer of LabConnect.

LabConnect首席开发官。

At the signing ceremony, Ms.

在签字仪式上，女士

Xu Yi

徐一

, Chairwoman of Teddy Laboratory/GuanHe Pharmaceuticals, stated 'LabConnect's unique business model aligns well with Teddy's localized strengths. Since our first Phase III clinical project together in 2022, we have successfully completed multiple international clinical trial collaborations.'

泰迪实验室/冠和制药董事长表示：“LabConnect 独特的商业模式与泰迪的本地化优势非常契合。自 2022 年首次合作开展 III 期临床项目以来，我们已经成功完成了多项国际临床试验合作。”

This strategic partnership marks not only a key milestone in Teddy Laboratories global expansion but also a deep integration of domestic and international central lab resources. In the future, both parties will continue working together to enhance global clinical trial service capabilities, support the development and launch of innovative drugs worldwide, and bring more advanced treatment options to patients..

这一战略合作不仅标志着泰格实验室全球布局的一个重要里程碑，也实现了国内外中心实验室资源的深度融合。未来，双方将继续携手，进一步提升全球临床试验服务能力，助力创新药物在全球的开发与上市，为患者带来更多的先进治疗选择。

About LabConnect

关于LabConnect

LabConnect is the leading provider of Central Laboratory Services, FSP and Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases. LabConnect's unique combination of state-of-the-art technology, world-class laboratories, easy access to major and emerging markets, and extensive specialized testing expertise means that drug development companies can rely on one provider for all their central laboratory service needs.

LabConnect 是中心实验室服务、功能性服务提供（FSP）和科学咨询以及数据集成与转换服务的领先提供商，专注于免疫肿瘤学、细胞和基因疗法以及罕见病和孤儿病等分析和物流复杂的研究。LabConnect 凭借尖端技术、世界级实验室、对主要市场和新兴市场的便捷覆盖，以及广泛的专业检测经验的独特组合，使药物开发公司能够依靠这一家供应商满足其中心实验室服务的所有需求。

Learn more at .

了解更多，请访问。

www.labconnect.com

and follow on

跟着做

领英

。

About Teddy Laboratory/GuanHe Pharmaceuticals

关于泰迪实验室/冠和制药

Shanghai GuanHe Pharmaceutical Technology Co., Ltd., established in 2016, is a leading innovative and integrated lab service platform in the clinical research industry. With branches in

上海观合医药科技有限公司成立于2016年，是临床研究领域领先的创新性综合性实验室服务平台，在多个城市设有分支机构。

Shanghai

上海

, Wuxi,

无锡，

Hangzhou

杭州

, and

，以及

Hong Kong

香港

, the company has built a one-stop service capability in central laboratory and bioanalysis, becoming an important player in full-chain clinical trial services. Teddy is a subsidiary controlled by Tigermed (300347.SZ / 3347.HK).

公司已构建起中心实验室和生物分析一站式服务能力，成为全链条临床试验服务的重要参与者。泰格益坦是泰格医药（300347.SZ / 3347.HK）控股子公司。

Teddy provides laboratory and scientific solutions to innovative drug companies to accelerate drug development and regulatory submissions. Its services span from biomarker discovery, target validation, patient enrichment, PK/PD studies, safety evaluation, to efficacy assessment and sample analysis. Teddy is committed to supporting clinical drug development with cutting-edge lab technologies.

特迪为创新药物公司提供实验室和科学解决方案，以加速药物开发和监管申报。其服务范围涵盖生物标志物发现、靶点验证、患者富集、药代动力学/药效学研究、安全性评估到疗效评估和样品分析。特迪致力于通过尖端的实验室技术支持临床药物开发。

As of .

截至。

March 2025

2025年3月

, Teddy has supported the approval of 37 new drugs and therapeutic products by

，泰迪支持批准了 37 种新药和治疗产品通过

China's

中国的

NMPA.

国家药品监督管理局

SOURCE LabConnect